#BHNL

Bispecific Antibodies May Reduce Relapse Risk Following HCT in B-Cell Lymphomas Using bispecific antibodies targeting CD20 and CD3 does not reduce efficacy or increase toxicity among patients with relapsed or refractory non-Hodgkin B-cell lymphomas undergoing HCT.

The use of bispecific antibodies targeting CD20 and CD3 does not reduce efficacy or increase toxicity among patients with relapsed or refractory #NonHodgekinLymphoma #BHNL (b-cell) undergoing allogeneic hematopoietic cell transplantation (HCT).

https://bit.ly/48W2qca

#HemOnc